Alerts will be sent to your verified email
Verify EmailWINDLAS
|
Windlas Biotech
|
Sakar Healthcare
|
NGL Fine-Chem
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
11.34 % | 8.14 % | 18.68 % |
|
5yr average Equity Multiplier
|
1.4 | 1.76 | 1.37 |
|
5yr Average Asset Turnover Ratio
|
0.99 | 0.45 | 1.03 |
|
5yr Avg Net Profit Margin
|
8.22 % | 10.03 % | 12.56 % |
|
Price to Book
|
3.05 | 5.5 | 6.0 |
|
P/E
|
26.69 | 49.45 | 41.01 |
|
5yr Avg Cash Conversion Cycle
|
-31.79 Days | 18.72 Days | 24.74 Days |
|
Inventory Days
|
37.94 Days | 51.79 Days | 47.94 Days |
|
Days Receivable
|
79.59 Days | 53.06 Days | 84.83 Days |
|
Days Payable
|
105.71 Days | 115.64 Days | 83.75 Days |
|
5yr Average Interest Coverage Ratio
|
43.11 | 4.85 | 25.7 |
|
5yr Avg ROCE
|
15.1 % | 8.92 % | 24.83 % |
|
5yr Avg Operating Profit Margin
|
11.87 % | 24.94 % | 18.08 % |
|
5 yr average Debt to Equity
|
0.02 | 0.49 | 0.16 |
|
5yr CAGR Net Profit
|
11.78 % | 10.38 % | -18.08 % |
|
5yr Average Return on Assets
|
8.11 % | 4.54 % | 13.76 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
63.31 % | 52.52 % | 72.49 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.49 % | -8.2 % | -1.04 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-4.75 % | 0.0 | 0.0 |
|
Windlas Biotech
|
Sakar Healthcare
|
NGL Fine-Chem
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
|
Segment Wise Break-Up
|
Segment Wise Break-Up
|
-
|
-
|